Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (July 2018)
53 slides from Ac Immune Sa's shareholder meeting presentation, Jul 6, 2018
Slide 1: Becoming a Global Leader in Precision Medicine of Neurodegenerative Diseases
BECOMING A GLOBAL LEADER IN PRECISION MEDICINE OF NEURODEGENERATIVE DISEASES © 2018 AC Immune. Not to be used or reproduced without permission. www.acimmune.com NASDAQ: ACIU | AGM | July 6, 2018
Slide 2: Disclaimer
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 1 Disclaimer This presentation may contain statements that constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Slide 3: Precision medicine in Alzheimer's disease
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 2 Precision medicine in Alzheimer’s disease Andrea Pfeifer CEO
Slide 4: Agenda
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 3 ▪ Alzheimer’s disease: updated facts ▪ ACIU: Precision Medicine as factor of differentiation ▪ Achievements 2017 ▪ Financial figures ▪ Pipeline & Catalysts 2017/18 ▪ People & Values ▪ Outlook Agend
Slide 5: Alzheimer's disease
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 4 Alzheimer’s disease
Slide 6: "…he was dead long before…"
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 5 “…he was dead long before…” William Utermohlen , Artistic decline through Alzheimer's disease 1996 1999 1997 2000 “He died in 2007 , but really he was dead long before that . ” Patricia Utermohlen
Slide 7: A growing problem…
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 6 A growing problem… Source: WHO; Alzheimer‘s Disease International, ADI; Nearly 10 million new cases every year
Slide 8: Increasing global burden and long-term market opportunities
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 7 Increasing global burden and long - term market opportunities …and a worldwide problem Re f: Rhoda, Boston University and Aging Well Institute, March 2017 29.9 15.8 9.4 15.8 7.0 4.0 18.6 13.4 10.5
Slide 9: Alzheimer's disease – a public health and costly problem
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 8 Alzheimer’s disease – a public health and costly problem Source: WHO; Alzheimer‘s Disease International, ADI;
Slide 10: AC Immune: Precision medicine as factor of differentiation
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 9 AC Immune: Precision medicine as factor of differentiations
Slide 11: Vision and Dual Proprietary Technology Platforms
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 10 Vision SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Morphomer TM Conformation - sensitive small molecules To become a global leader in precision medicine 1 of
Slide 12: Precision medicine creates ultimate differentiation
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 11 Precision medicine creates ultimate differentiation Business strategy: 3 - pillar approach Vision Alzheimer’s disease (AD) Non - AD Neuro - orphans Diagnostics Technology platforms Values ▪ Develo
Slide 13: Early diagnosis translates into earlier treatment and better outcome
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 12 Early diagnosis translates into earlier treatment and better outcome Alzheimer’s disease treatment Genetic diagnosis Imaging diagnosis Clinical diagnosis Genetic diagnosis ▪ The future treatment p
Slide 14: AC Immune: a leader in neurodegenerative diseases
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 13 AC Immune: a leader in neurodegenerative diseases Investment highlights Pioneering precision medicine in neurodegenerative diseases, a significant unmet medical need and potentially largest market
Slide 15: AC Immune: Achievements 2017
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 14 AC Immune: Achievements 2017
Slide 16: Highlights and achievements 2017/18: Finance and Business Operations
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 15 Highlights and achievements 2017/18 Finance and Business Operations ▪ Strong cash position of 109.7 million (Q1 2018) provides resources to advance pipeline of nine therapeutic and three diagnosti
Slide 17: Highlights and achievements 2017/18: Finance and Business Operations
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 16 Highlights and achievements 2017/18 Finance and Business Operations ▪ Entered research collaboration agreement with Essex Bio - Technology for development of novel biological therapeutic for the t
Slide 18: Highlights and achievements 2017/18: Clinical stage programs
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 17 Highlights and achievements 2017/18 Clinical stage programs ▪ Crenezumab 1 : ▪ Second pivotal Phase 3 trial of CREAD 2 initiated in 750 subjects with prodromal to mild Alzheimer’s disease in Q1 20
Slide 19: Highlights and achievements 2017/18: Pre-clinical stage programs
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 18 Highlights and achievements 2017/18 Pre - clinical stage programs supporting ACIU’s Precision Medicine approach ▪ A - synuclein - PET tracer 1 : Discovered potentially first selective alpha - synu
Slide 20: AC Immune: Finance
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 19 AC Immune: Finance Joerg Hornstein CFO
Slide 21: Key financial data
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 20 Key financial data Financial overview (all figures in CHF millions, except for share and per share data) Twelve months ended December 31, 2017 Twelve months ended December 31, 2016 Income statemen
Slide 22: Pipeline & Catalysts for 2018/19
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 21 Pipeline & Catalysts for 2018/19
Slide 23: Broad and robust pipeline in neurodegenerative diseases
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 22 Driven by proprietary technology platforms for sustained growth Broad and robust pipeline in neurodegenerative diseases Biologics Diagnostics Small molecules Crenezumab (anti - Abeta antibody) tre
Slide 24: Multiple near-term catalysts for 2018/19
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 23 Successful delivery of s trategy with multiple near - term catalysts for 2018/19 Data read - outs Study initiations ▪ ACI - 24 in AD Phase 2 recruitment in 2018 ▪ ACI - 35 next phase of developmen
Slide 25: AC Immune: People & Values
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 24 AC Immune: People & Values
Slide 26: Statistics
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 25 Statistics HR statistics as of December 2017 ▪ 19 nationalities spread over the world ▪ More than 20 spoken languages ▪ Equally treatment of salaries between male and female ▪ Gender balance: 55%
Slide 27: AC Immune values
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 26 ENTRE - PRENEURSHIP is our attitude AC Immune values OPERATIONS MANAGEMENT we keep AC Immune rolling INNOVATION we create and innovate LEADERSHIP we make it happen COMMUNICATION we know we will ge
Slide 28: Strategic outlook
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 27 Strategic outlook
Slide 29: Strategy for value creation
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 28 Strategy for value creation EVOLVE strategy and capture upside by developing late stage assets in - house CONTINUE to leverage our dual platform technologies to efficiently advance commercially vi
Slide 30: Agenda items and proposals of the Board of Directors
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 29 Agenda items and proposals of the Board of Directors
Slide 31: Agenda
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 30 Agenda 1. Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017 2. Appropriation of Loss 3. Discharge of the Me
Slide 32: Approval of the Annual Report and Financial Statements 2017
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 31 Agenda item 1 ▪ The Board proposes to approve the Annual Report, the Annual Statutory Financial Statements and the Financial Statements under IFRS of AC Immune SA for the year 2017, and to take no
Slide 33: Appropriation of Loss
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 32 Agenda item 2 ▪ The Board of Directors proposes that the net loss of the year 2017 in the amount of KCHF 25’868 is added to the loss brought forward of KCHF 32’558 resulting in a reduced new balan
Slide 34: Discharge of the Board of Directors and Executive Committee
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 33 Agenda item 3 ▪ The Board proposes that the members of the Board and the Executive Committee are discharged from their liabilities for their activities in the financial year 2017 . Discharge of th
Slide 35: Compensation for the Board and Executive Committee
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 34 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and the Executive Co
Slide 36: Compensation: Board non-performance-related compensation
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 35 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and the Executive Co
Slide 37: Compensation: Equity for Board members
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 36 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and the Executive Co
Slide 38: Compensation: Executive Committee non-performance-related
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 37 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and the Executive Co
Slide 39: Compensation: Executive Committee variable compensation
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 38 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and the Executive Co
Slide 40: Compensation: Equity for Executive Committee
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 39 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and the Executive Co
Slide 41: Election of the Members of the Board
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 40 Agenda item 5 ▪ The Board of Directors proposes the re - election of Martin Velasco as member and as Chairman of the Board, Peter Bollmann , Friedrich von Bohlen, Andrea Pfeifer, Detlev Riesner ,
Slide 42: Dr. Werner Lanthaler
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 41 Dr. Werner Lanthaler
Slide 43: Dr. Werner Lanthaler
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 42 Dr. Werner Lanthaler ▪ CEO of Evotec AG since 2009 ▪ Previously served as: ▪ CFO Intercell AG ▪ Director of the Federation of Austrian Industry ▪ Non - executive member of the Board of directors o
Slide 44: Election of the Members of the Board
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 43 Agenda item 5 ▪ The Board of Directors proposes the re - election of Martin Velasco as member and as Chairman of the Board, Peter Bollmann , Friedrich von Bohlen, Andrea Pfeifer, Detlev Riesner ,
Slide 45: Election to the Compensation, Nomination & Corporate Governance Committee
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 44 Agenda item 6 ▪ The Board of Directors proposes the re - election of Martin Velasco, Tom Graney and Douglas Williams as members of the Compensation, Nomination & Corporate Governance Committee, ea
Slide 46: Re-election of the independent proxy
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 45 Agenda item 7 ▪ The Board of Directors proposes that Bugnion Ballansat Ehrler , represented by Gérald Virieux , avocat , rue de Rive 6, case postale 3143, CH - 1211 Geneva 3 shall be re - elected
Slide 47: Election of the Auditors
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 46 Agenda item 8 ▪ The Board of Directors proposes to elect PricewaterhouseCoopers SA, in Pully , for a term of office of one year. Election of the Auditors
Slide 48: Share Capital Increase
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 47 Share Capital Increase Joerg Hornstein CFO
Slide 49: Agenda item 9: Share Capital Increase
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 48 Background Rationale Agenda item 9: Share Capital Increase ▪ Shareholder approval is required under Swiss law for a company to increase its share capital ▪ Previous timeline for increase of author
Slide 50: Extension of Authorization for Share Capital Increase
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 49 Agenda item 9 ▪ The Company's Extraordinary Shareholders' Meeting of 27 April 2018 authorized the Board of Directors to increase the share capital of the Company by 26 July 2018. The Board propose
Slide 51: Agenda item 9a
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 50 Agenda item 9a a) the share capital of the Company is increased by way of an ordinary increase by up to CHF 170'000 by issuing up to 8'500'000 registered shares with a nominal value of CHF 0.02 ea
Slide 52: Agenda item 9b
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 51 Agenda item 9b a) the share capital of the Company is increased by way of an ordinary increase of by up to CHF 30'000 by issuing up to 1'500'000 registered shares with a nominal value of CHF 0.02
Slide 53: We thank you for coming and your continued support
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | AGM | July 6, 2018 52 We thank you for coming and your continued support .